Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04634825 · ClinicalTrials.gov registry record · Phase 2
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer
A Phase 2 study, sponsored by MacroGenics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT04634825 is a Phase 2 study that was terminated before completion, run by MacroGenics. The registered enrollment target is 62 participants.
The verdict
NCT04634825, a Phase 2 study, was terminated before completion, sponsored by MacroGenics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Interventions
- BIOLOGICAL Retifanlimab
- BIOLOGICAL Tebotelimab
- BIOLOGICAL Enoblituzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2021-03-17 |
| Est. Completion | 2022-07-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04634825
The ClinicalTrials.gov registry entry for NCT04634825 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MacroGenics, which has 36 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Retifanlimab is the first listed.
NCT04634825 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04634825 about?
NCT04634825 is a clinical study titled "Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer". This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
What is the current status of trial NCT04634825?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2021-03-17. Estimated completion is 2022-07-29.
What interventions are being tested in trial NCT04634825?
The interventions under investigation include: Retifanlimab (BIOLOGICAL), Tebotelimab (BIOLOGICAL), Enoblituzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT04634825?
This trial is sponsored by MacroGenics, which has 36 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.